Update research from QuotedData

RNS Number : 5781I
Intl. Biotechnology Trust PLC
02 April 2020
 

 

International Biotechnology Trust - Update research from QuotedData

 

2nd April 2020

 

Trust in biotech

 

The biotechnology sector is proving to be relatively resilient in this COVID-19 related market sell-off. International Biotechnology Trust (IBT) adopts a conservative approach to investing in what can be a quite volatile, if rewarding, sector. It has fared better than competing funds in this environment.

 

Some delay to drug development, testing programmes and product launches may be inevitable as the world focuses on tackling the coronavirus. However, the underlying picture for biotechnology is one of strong growth, as companies bring forward cures for previously untreatable diseases, based on advances in the likes of gene therapy (where faulty genes are replaced) and immunotherapy (where the body's immune system is encouraged to attack target cells). The race for the White House, which was one source of uncertainty, seems likely to be between Trump and Biden, which could mean business as usual for the drug companies.

 

Full research:

 

https://quoteddata.com/research/international-biotechnology-trust-trust-biotech/

 

This research is also available free on our website www.quoteddata.com where you will also find news, performance data and factsheets on every London listed Investment Company. QuotedData writes and distributes research on a number of quoted companies, facilitates meetings between those companies and existing and potential investors and assists in raising additional capital where required.

NB: Marten & Co was paid to produce this note on International Biotechnology Trust and it is for information purposes only. It is not intended to encourage the reader to deal in the security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which is authorised and regulated by the FCA. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of the Financial Conduct Authority.

QUOTEDDATA
123a Kings Road | London SW3 4PL
Tel: +44 (0) 20 3691 9430

www.quoteddata.com | research@quoteddata.com | www.martenandco.com  


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUUARRRVUSRAR
UK 100

Latest directors dealings